Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 243.38B +1.1% |
| Revenue (ttm) | 55.37B +1.3% |
| Net Income | 15.55B +6.6% |
| EPS | 6.20 +8.0% |
| Shares Out | n/a |
| PE Ratio | 15.65 |
| Forward PE | n/a |
| Dividend | 2.86 (2.91%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 11,377 |
| Average Volume | 3,094 |
| Open | 95.50 |
| Previous Close | 95.10 |
| Day's Range | 93.00 - 100.60 |
| 52-Week Range | 65.50 - 100.60 |
| Beta | 0.30 |
| RSI | 68.56 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.
Financial numbers in USD Financial StatementsNews
4 stocks to watch on Tuesday: PFE, MRK, HPQ, PYPL
Stock futures rise as investors eye 4 stocks to watch—Merck, HP, Pfizer and PayPal—on earnings, guidance and CEO changes.
Merck 2026 Outlook Misses as Gardasil Sales Drop 35%
Merck 2026 Outlook Misses as Gardasil Sales Drop 35%
Leisure Capital Management Sells 579 Shares of Merck & Co Inc (MRK)
Leisure Capital Management Sells 579 Shares of Merck & Co Inc (MRK)
Goldman Sachs Equal Weight U.S. Large Cap Equity ETF Buys 1,019 Shares of Merck & Co Inc (MRK)
Goldman Sachs Equal Weight U.S. Large Cap Equity ETF Buys 1,019 Shares of Merck & Co Inc (MRK)
Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Horst & Graben Wealth Management LLC Buys 2,376 Shares of Merck & Co Inc (MRK)
Horst & Graben Wealth Management LLC Buys 2,376 Shares of Merck & Co Inc (MRK)
Merck (MRK) Stock Dips on Disappointing 2026 Outlook
Merck (MRK) Stock Dips on Disappointing 2026 Outlook
Merck (MRK) Surpasses Earnings and Revenue Expectations
Merck (MRK) Surpasses Earnings and Revenue Expectations
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
These are the stocks posting the largest moves in early trading.
Merck tops Q4 earnings expectations but issues weaker 2026 outlook
Merck closed the fourth quarter with earnings and revenue ahead of Wall Street estimates, supported by strong demand for its blockbuster cancer drug Keytruda and accelerating sales from newer medicine...
ROUNDUP: Merck Guides FY26 Below Estimates
KENILWORTH (NJ) (dpa-AFX) - While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initia...
Merck stock dips as 2026 outlook falls short of expectations
Merck (MRK) stock slides after weak 2026 outlook; Keytruda grows, Gardasil slumps, cost cuts noted.
Merck (MRK) Surpasses Q4 Earnings Expectations
Merck (MRK) Surpasses Q4 Earnings Expectations
Merck’s outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year
Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.
Merck (MRK) Projects Revenue Between $65.5B and $67B for FY26
Merck (MRK) Projects Revenue Between $65.5B and $67B for FY26
Merck (MRK) Faces One-Time Charge Due to Cidara Acquisition
Merck (MRK) Faces One-Time Charge Due to Cidara Acquisition
Merck in Charts: Q4 sees pharmaceutical sales up ~6% Y/Y, led by 7% rise in KEYTRUDA
Earnings Snapshot: Merck tops Q4, issues weaker-than-expected FY profit and sales outlook
Merck Earnings Top Estimates. Why the Stock Is Falling.
Merck says 2026 earnings will take a hit due to its pending takeover of Cidara Therapeutics.
Merck Expects Slower Earnings Growth As It Spends on Acquisitions
Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions.
Merck forecasts 2026 sales below estimates on patent losses
Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates as the loss of patent exclusivity on diabetes drug Januvia and other medicines will hit harder than analysts are proje...
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
Merck Non-GAAP EPS of $2.04 beats by $0.03, revenue of $16.4B beats by $190M
Dow Jones Giant Merck Crushes Fourth-Quarter Views. But Guidance Could Shake Shares.
Merck quashed fourth-quarter expectations Tuesday, but the Dow Jones health giant issued lackluster expectations for 2026.
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results.